Fri., 10/17/08 Geriatrics/Reconstruction, Paper #35, 4:00 pm OTA-2008
Brian D. Solberg, MD (e-Stryker, Zimmer); Charles N. Moon, MD (e-Stryker, Zimmer);
Dennis P. Franco, MD (n); Guy D. Paiement, MD (n);
Cedars Sinai Medical Center, Los Angeles, California, USA
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #36, 4:06 pm OTA-2008
Edward Yang, MD1 (n); Sheeraz Qureshi, MD2 (n);
Shawn Trokhan, MD2 (n); David Joseph, MD1 (n);
1Elmhurst Hospital Center, Elmhurst, New York, USA;
2Mt. Sinai School of Medicine, New York, New York, USA
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #37, 4:12 pm OTA-2008
Timothy J. S. Chesser, MD (a-Stryker); David Copas, MD (n); Rebecca Fox (n);
Tristan M. Barton, MD (n); Claire Topliss, MD (n); Robert Gleeson, MD (n); William J. Harries, MD (n);
Department of Orthopaedic Trauma, Frenchay Hospital, North Bristol NHS Trust, Bristol, United Kingdom
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #38, 4:18 pm OTA-2008
Are Serum Albumin and Total Lymphocyte Count Accurate Predictors of Outcome in Hip Fractures?
Brendan J. O’Daly, MD1 (n); James C. Walsh, MD1 (n); John F. Quinlan, MD1 (n);
Robert Stapleton, PhD2 (n); William R. Quinlan, MD1 (n); Kieran O’Rourke, MD1 (n);
1Department of Orthopaedic Surgery, St. Vincent’s University Hospital, Dublin, Ireland;
2Department of Statistics, National University of Ireland, Maynooth, Ireland
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #39, 4:34 pm OTA-2008
Joshua L. Gary, MD1 (n); Frank Gerold, MS2 (n);
Kelly A. Lefaivre, MD1 (a-AO North America, Zimmer); Adam J. Starr, MD1 (n);
Charles M. Reinert, MD1 (n);
1University of Texas Southwestern Medical Center, Dallas, Texas, USA;
2University of Texas Health Science Center at Houston, Houston, Texas, USA
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #40, 4:40 pm OTA-2008
Anterior Hip Arthroplasty for Treatment of Acute Displaced Elderly Femoral Neck Fractures
Kurtis Staples, MD (n); Philip J. Kregor, MD (a-AO Research Foundation, Synthes);
Vanderbilt Orthopaedic Institute, Nashville, Tennessee, USA
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #41, 4:46 pm OTA-2008
The Use of Clopidogrel (Plavix) in Patients Undergoing Non-Elective Orthopaedic Surgery
Jason A. Nydick, DO1 (n); Eric D. Farrell, MD1 (a-Synthes; e-DePuy);
Andrew J. Marcantonio, DO2 (n); Eric L. Hume, MD1 (a-Synthes; e-Stryker);
Shawn W. Storm, DO1 (a-Synthes); Robert Marburger, RN, CCRC1 (a-Synthes);
Robert F. Ostrum, MD1 (a-Synthes, e-DePuy, Biomet);
1Cooper University Hospital, Camden, New Jersey, USA;
2Lahey Clinic Medical Center, Department of Orthopaedic Surgery,
Burlington, Massachusetts, US
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #42, 4:59 pm OTA-2008
A Prospective Trial of Autologous Growth Factor versus Iliac Crest Bone Graft
David A. Volgas, MD (a-Biomet (Interport-Cross), Smith + Nephew, Synthes, Pfizer);
James P. Stannard, MD (a-Smith + Nephew, Synthes);
Rena L. Stewart, MD (a-Synthes, Wyeth); Benton Emblom, MD (n);
Jorge Alonso, MD (e-Synthes);
University of Alabama at Birmingham, Birmingham, Alabama, USA
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #43, 5:05 pm OTA-2008
Maintenance of Hardware after Early Postop Infection following Fracture Internal Fixation
The Southeast Fracture Consortium;
William T. Obremskey, MD, MPH (a-Synthes; e-Medtronic, Osteogenix);
Vanderbilt University, Nashville, Tennessee, USA
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #44, 5:16 pm OTA-2008
Renn J. Crichlow, MD (n); Amer Zeni, MD (n); Greg Reveal, MD (n); Mitch Kuhl, MD (n);
Jason Heisler, DO (n); David Kaehr, MD (n); Palaniswamy Vijay, PhD (n);
OrthoIndy, Indianapolis, Indiana, USA
Fri., 10/17/08 Geriatrics/Reconstruction, Paper #45, 5:22 pm OTA-2008
Financial Viability of an Orthopaedic Trauma System
Peter L. Althausen, MD, MBA (n); Daniel Coll, BS, PA-C (n);
Michael Cvitash, BMS, PA-C (n); Timothy J. O’Mara, MD (n); Timothy J. Bray, MD (n);
Reno Orthopedic Clinic, Reno, Nevada, USA
If noted, the author indicates something of value received. The codes are identified as a-research or institutional support; b-miscellaneous funding; c-royalties; d-stock options; e-consultant or employee; n-no conflicts disclosed, and *disclosure not available at time of printing.
• The FDA has not cleared this drug and/or medical device for the use described in this presentation (i.e., the drug or medical device is being discussed for an “off label” use). ◆FDA information not available at time of printing. Δ OTA Grant.